InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,789.72
(
1.55%
)
Post# of 252588
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: croumagnon post# 40121

Tuesday, 01/02/2007 5:52:01 PM

Tuesday, January 02, 2007 5:52:01 PM

Post# of 252588
The gutting of DNDN's pipeline due to halting all work on everything but the Provenge BLA, no early-stage PCa trials on the horizon for Provenge, and two financings at $4.50 are perfect examples of why management teams should partner their first drugs even if the deals are not perfect.

At this point, let's all cross our fingers and hope the advisory panel is feeling patient-focused and reasonable that day.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up